A deficiency in the HRR pathway has been associated with several tumor types including breast, ovarian, prostate, and pancreatic cancers (Fig. 1) and has been termed homologous recombination deficiency (HRD), whereas tumors that are not HRD are termed homologous recombination proficient (HRP).